Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313771 | 1.00 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL30313812 | 0.95 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL22405012 | 0.95 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL22405015 | 0.92 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL30091777 | 0.92 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL22400967 | 0.90 | EGFR (0.82) | EGFRBTK | |
| SCHEMBL22405032 | 0.87 | EGFR (0.83) | EGFRBTK | |
| SCHEMBL30313815 | 0.86 | EGFR (0.75) | EGFRBTK | |
| SCHEMBL22400976 | 0.86 | EGFR (0.75) | EGFRBTK | |
| SCHEMBL22400871 | 0.85 | EGFR (1.00) | EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278818-B | BTK inhibitor compounds | 伊莱利利公司 | 2023-03-28 | — | — | CN | claimed |
| EP-3707133-A1 | BTK INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2020-09-16 | — | — | EP | claimed |
| CN-111278818-A | BTK inhibitor compounds | 伊莱利利公司 | 2020-06-12 | — | — | CN | claimed |
| CN-111278818-B | BTK inhibitor compounds | 伊莱利利公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| CN-111278818-A | BTK inhibitor compounds | 伊莱利利公司 | 2020-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | EGFR 403/4885BTK 1/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | EGFR 380/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.